https://scholars.lib.ntu.edu.tw/handle/123456789/202423
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 檢驗醫學科 | en |
dc.contributor.author | HSU, JENG-YUAN | en |
dc.contributor.author | PENG, JUI-PENG | en |
dc.contributor.author | LU, JAU- YEONG | en |
dc.contributor.author | WU, CHIN-PYNG | en |
dc.contributor.author | HUANG, MING-SHYAN | en |
dc.contributor.author | LUH, KWEN-TAY | en |
dc.contributor.author | YANG, PAN-CHYR | en |
dc.creator | 許正園;彭瑞鵬;盧朝勇;吳清平;黃明賢;陸坤泰;楊泮池 | zh-tw |
dc.creator | HSU, JENG-YUAN;PENG, JUI-PENG;LU, JAU- YEONG;WU, CHIN-PYNG;HUANG, MING-SHYAN;LUH, KWEN-TAY;YANG, PAN-CHYR | en |
dc.date | 2006 | en |
dc.date.accessioned | 2009-09-25T01:26:33Z | - |
dc.date.accessioned | 2018-07-12T09:25:12Z | - |
dc.date.available | 2009-09-25T01:26:33Z | - |
dc.date.available | 2018-07-12T09:25:12Z | - |
dc.date.issued | 2006 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/94631 | - |
dc.description.abstract | Background/Purpose: To compare the efficacy and safety of tiotropium and ipratropium in patients with chronic obstructive pulmonary disease (COPD) in Taiwan. Methods: This double-blind, randomized, placebo-controlled, parallel group study was conducted at six hospitals in Taiwan. COPD patients aged : 40 years, with a forced expiratory volume in 1 second (FEV 1) <= 65% of predicted and FEV1/forced vital capacity (FVC) <= 70% were enrolled. After a 2-week screening/baseline period, 132 patients were randomized to receive 4 weeks of treatment with either tiotropium 18 mu g once daily from a dry powder inhaler (HandiHaler (R)) or two puffs of ipratropium 20 mu g four times daily from a metered dose inhaler. The primary outcome was the change in trough FEV1 from baseline to week 4. The secondary outcome measures were trough FVC response, FEV1 and FVC responses at 2 hours postinhalation. Results: After 4 weeks, trough FEV1 had increased by 61.7 +/- 25.3 mL for tiotropium but decreased by 16.4 27. 9 mL for ipratropium. The difference between groups was significant (p < 0 .05; 95% Cl, 10-146.1). The trough FVC also increased by 137.2 +/- 49.3 ml , for tiotropium but was decreased by 84.5 +/- 54.5 ml, for ipratropium (p < 0.001; 95% Cl, 89.0-354.3). No major drug- related adverse events associated with tiotropium and ipratropium were observed. Conclusion: Tiotropium 18 mu g once daily using HandiHater (R) was significantly more effective than ipratropium 40 mu g four times daily in improving trough FEV1 and FVC over a 4-week period. The safety profiles of both drugs are comparable. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION v.105 n.9 pp.708-714 | en |
dc.relation.ispartof | JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | - |
dc.subject | chronic obstructive | en |
dc.subject | pulmonary disease HandiHaler | en |
dc.subject | ipratropium | en |
dc.subject | metered dose inhaler | en |
dc.subject | tiotropium | en |
dc.title | Double-Blind Randomized Parallel Group Study Comparing the Efficacy and Safety of Tiotropium and Ipratropium in the Treatment of Copd Patients in Taiwan | en |
dc.relation.pages | 708-714 | - |
dc.relation.journalvolume | v.105 | - |
dc.relation.journalissue | n.9 | - |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en_US | - |
item.grantfulltext | none | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。